Navigation Links
PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Date:3/5/2012

ANNAPOLIS, Md., March 5, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the ROTH 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Event:

24th Annual ROTH ConferenceDate:

Monday, March 12, 2012 at 5:30 pm Place:

Ritz-Carlton Laguna Niguel, Salon 1Time:

5:30 pm PTAbout PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit www.PharmAthene.com.


    '/>"/>
    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
    3. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    4. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    5. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    6. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    7. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    9. PharmAthene Completes $6.5 Million Registered Direct Offering
    10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    11. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/11/2017)... ... 2017 , ... “There is an increasing consumer call for ... ingredients,” said Matt Hundt, President of Third Wave Bioactives. “Combining the strong discovery ... of Biorigin will allow us to bring truly novel fermented ingredient technologies to ...
    (Date:8/10/2017)... ... August 09, 2017 , ... ... in the clinic is here. The team at Capricor Therapeutics, Inc. utilized a ... for clinical studies. , Dr. Travis Antes, head of analytical development at ...
    (Date:8/10/2017)... ... August 09, 2017 , ... ... international biomedical optics laboratories — the Wellman Center for Photomedicine, the Manstein Lab ... Lübeck and the Beckman Laser Institute at University of California, Irvine — and ...
    (Date:8/10/2017)... FL (PRWEB) , ... August 10, 2017 , ... ... that the stock market news outlet had initiated coverage on Next Group Holdings, ... growing and underserved consumer markets geared toward those that cannot engage in traditional ...
    Breaking Biology Technology:
    (Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
    (Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
    (Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
    Breaking Biology News(10 mins):